Boundless Bio Inc BOLD
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-03-28 |
| Shares Out. | 22,470,000 |
| Website | boundlessbio.com/ ↗ |
| Phone | 18587669912 |
| Employees | 28 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$23.7M |
| Free Cash Flow | -$56.7M |
| Total Assets | $73.7M |
| Total Liabilities | $7.8M |
| Equity | $66.0M |
About Boundless Bio Inc
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Boundless Bio Inc is a publicly traded company under the ticker symbol BOLD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-09-01)